{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Research Survey

  1. What is the approximate percentage of open-angle glaucoma patients whose intraocular pressure (IOP) is uncontrolled, as observed in your practice?
    2. Number of drugs for treatment of open angle glaucoma Percentage of patients uncontrolled
    1 Drug *
    2 Drugs *
    3 Drugs *
  2. What is the approximate percentage of POAG (primary open-angle glaucoma) patients whom you choose to prescribe Netarsudil, as observed in your practice? *

  3. What is your preference for Netarsudil in patients with glaucoma, as per based on your practice? *

  4. How would you rate your experience with newly introduced ROCK Inhibitor Netarsudil in POAG (primary open-angle glaucoma) as an add on to below class of drug therapy (Tick in front of appropriate option)
    5. Parameter Strongly recommended Recommended Neutral Yet to try

    Prostaglandin analogues (PGA) *

    Carbonic anhydrase inhibitors (CAI)*

    β-Adrenergic receptor blockers *

    α-Adrenergic receptor agonists *

  5. How would you rate your experience with newly introduced ROCK Inhibitor Netarsudil in POAG (Primary open-angle glaucoma) patients in terms of (Tick in front of appropriate option)?
    6. Parameter Strongly recommended Recommended Neutral Yet to try

    Efficacy *

    Tolerability *

  6. Which is your preferred choice of anti-glaucoma medication in treatment naive patients with Normal Tension Glaucoma ( NTG ) (Kindly tick appropriate option): *

  7. Which is your preferred Add-on anti-Glaucoma medication, when IOP is not sufficiently controlled on PGA monotherapy *

  8. What are the common adverse events experienced by your patients who are on Netarsudil therapy *

  9. How many percentage of patients drop out of treatment due to adverse reactions of Netarsudil, as observed in your practice? *

  10. Would you consider using Netarsudil in patients instead of Timolol as both of them have equivalent IOP reduction as per clinical studies in patients with open angle glaucoma (OAG)? *

  11. Which is your preferred treatment option in patients with POAG in terms of efficacy, safety, below comorbid conditions & age group specific patient profiles? (Kindly tick at appropriate option)
    12. IOP lowering efficacy Safety Cardio-vascular comorbidity Elderly >60 yrs of age

    Netarsudil *

    Timolol *

  12. Which is your most preferred class of drugs in patients with steroid induced glaucoma *

  13. Netarsudil as a molecule requires maintenance of end-to-end cold chain, how would you rate your experience with Raiki in terms of this claim & the benefits to the patients? *

  14. In which patients age group with POAG would you prefer Netarsudil , as per your clinical practice? *

  15. Which are the criteria that you consider for considering Netarsudil over Beta- blocker in open angle glaucoma (OAG) patients? *

(POAG: Primary Open Angle Glaucoma, IOP: Intraocular Pressure, PGA: Prostaglandin Analogues, VF: Visual Field, ROCK: Rhokinase inhibitors)